nach oben

Erschienen in:

15.12.2016 | Original articles

miR-539 as a key negative regulator of the MEK pathway in myocardial infarction

verfasst von: J. Hui, W. Huishan, PhD, L. Tao, Y. Zhonglu, Z. Renteng, H. Hongguang

Erschienen in: Herz | Ausgabe 8/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

Myocardial infarction is one of the most common causes of death, and the number of individuals at risk is increasing. A rapid and accurate differential diagnosis of myocardial infarction is crucial for timely interventions and for improvement of the prognosis. However, it is difficult to achieve using current methods. To better manage this condition, improved tools for risk prediction, including more accurate biomarkers, are needed.

Methods

We studied the expression of microRNA-539 (miR-539) and of MEK protein using a rat model of myocardial infarction.

Results

The results of our experiments demonstrated an increase in the expression of miR-539 and a decrease in the expression of MEK. Furthermore, we observed that miR-539 inhibited the expression of MEK through targeting of the 3’UTR of MEK; this led not only to suppressed proliferation but also to apoptosis and autophagy of H9C2 cells.

Conclusion

Overexpression of miR-539 plays a role in the degree of myocardial infarction. On the basis of our results, we conclude that miR-539 may be a potential therapeutic target for myocardial infarction.

Lee RC, Feinbaum RL, Ambros V (1993) The c. Elegans heterochronic gene lin-4 encodes small rnas with antisense complementarity to lin-14. Cell 75:843–854CrossRefPubMed

Bartel DP (2004) Micrornas: genomics, biogenesis, mechanism, and function. Cell 116:281–297CrossRefPubMed

Vasilatou D, Papageorgiou S, Pappa V et al (2010) The role of micrornas in normal and malignant hematopoiesis. Eur J Haematol 84:1–16

Garzon R, Croce CM (2008) Micrornas in normal and malignant hematopoiesis. Curr Opin Hematol 15:352–358CrossRefPubMed

Huang XA, Lin H (2012) The mirna regulation of stem cells. Wiley Interdiscip Rev Membr Transp Signal 1:83–95PubMed

Seeger FH, Zeiher AM, Dimmeler S (2013) Micrornas in stem cell function and regenerative therapy of the heart. Arterioscler Thromb Vasc Biol 33:1739–1746CrossRefPubMed

Di Leva G, Calin GA, Croce CM (2006) Micrornas: Fundamental facts and involvement in human diseases. Birth Defects Res C Embryo Today Rev 78:180–189CrossRef

Thum T, Catalucci D, Bauersachs J (2008) Micrornas: Novel regulators in cardiac development and disease. Cardiovasc Res 79:562–570CrossRefPubMed

Lee Y, Ahn C, Han J et al (2003) The nuclear RNase III Drosha initiates microRNA processing. Nature 425:415–419

10.

Krek A, Grun D, Poy MN et al (2005) Combinatorial microrna target predictions. Nat Genet 37:495–500

11.

Thomas M, Lieberman J, Lal A (2010) Desperately seeking microrna targets. Nat Struct Mol Biol 17:1169–1174CrossRefPubMed

12.

Lytle JR, Yario TA, Steitz JA (2007) Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5’ UTR as in the 3’ UTR. Proc Natl Acad Sci USA 104:9667–9672CrossRefPubMedPubMedCentral

13.

Qin W, Shi Y, Zhao B et al (2010) Mir-24 regulates apoptosis by targeting the open reading frame (orf) region of faf1 in cancer cells. PLOS ONE 5:e9429

14.

Catalucci D, Gallo P, Condorelli G (2009) Micrornas in cardiovascular biology and heart disease. Circ Cardiovasc Genet 2:402–408CrossRefPubMed

15.

van Rooij E (2011) The art of microrna research. Circ Res 108:219–234CrossRefPubMed

16.

Liu Q, Du GQ, Zhu ZT et al (2015) Identification of apoptosis-related micrornas and their target genes in myocardial infarction post-transplantation with skeletal myoblasts. J Transl Med 13:270

17.

Hu S, Huang M, Li Z et al (2010) MicroRNA-210 as a novel therapy for treatment of ischemic heart disease. Circulation 122:S124–S131

18.

Ikeda S, Kong SW, Lu J et al (2007) Altered microrna expression in human heart disease. Physiol Genomics 31:367–373

19.

Devaux Y, Vausort M, McCann GP et al (2013) MicroRNA-150: A novel marker of left ventricular remodeling after acute myocardial infarction. Circ Cardiovasc Genet 6:290–298

20.

Topkara VK, Mann DL (2011) Role of micrornas in cardiac remodeling and heart failure. Cardiovascular drugs and therapy/sponsored by the International Society of Cardiovascular. Pharmacotherapy 25:171–182

21.

Li Q, Xie J, Li R et al (2014) Overexpression of microrna-99a attenuates heart remodelling and improves cardiac performance after myocardial infarction. J Cell Mol Med 18:919–928

22.

Wang K, Long B, Zhou LY et al (2014) Carl lncrna inhibits anoxia-induced mitochondrial fission and apoptosis in cardiomyocytes by impairing mir-539-dependent phb2 downregulation. Nat Commun 5:3596

23.

Muthusamy S, DeMartino AM, Watson LJ et al (2014) Microrna-539 is up-regulated in failing heart, and suppresses o‑glcnacase expression. J Biol Chem 289:29665–29676

24.

Hu YW, Hu YR, Zhao JY et al (2014) An agomir of mir-144-3p accelerates plaque formation through impairing reverse cholesterol transport and promoting pro-inflammatory cytokine production. PLOS ONE 9:e94997

25.

Guo B, Zhang Y, Hui Q et al (2016) Naringin suppresses the metabolism of A375 cells by inhibiting the phosphorylation of c‑Src. Tumour Biol 37(3):3841–3850

26.

Xu L, Yates CC, Lockyer P et al (2014) MMI-0100 inhibits cardiac fibrosis in myocardial infarction by direct actions on cardiomyocytes and fibroblasts via mk2 inhibition. J Mol Cell Cardiol 77:86–101

27.

Dorn GW 2nd (2009) Novel pharmacotherapies to abrogate postinfarction ventricular remodeling. Nat Rev Cardiol 6:283–291CrossRefPubMed

28.

Perera RJ, Ray A (2007) Micrornas in the search for understanding human diseases. BioDrugs 21:97–104CrossRefPubMed

29.

Bostjancic E, Zidar N, Glavac D (2009) Microrna microarray expression profiling in human myocardial infarction. Dis Markers 27:255–268CrossRefPubMed

30.

Fasanaro P, D’Alessandra Y, Di Stefano V et al (2008) Microrna-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand ephrin-a3. J Biol Chem 283:15878–15883

31.

Zhou L, Qi X, Potashkin JA et al (2008) Micrornas mir-186 and mir-150 down-regulate expression of the pro-apoptotic purinergic p2x7 receptor by activation of instability sites at the 3’-untranslated region of the gene that decrease steady-state levels of the transcript. J Biol Chem 283:28274–28286

32.

Zhu H, Fan GC (2012) Role of micrornas in the reperfused myocardium towards post-infarct remodelling. Cardiovasc Res 94:284–292CrossRefPubMed

33.

Lee YN, Brandal S, Noel P et al (2011) Kit signaling regulates mitf expression through mirnas in normal and malignant mast cell proliferation. Blood 117:3629–3640

Titel: miR-539 as a key negative regulator of the MEK pathway in myocardial infarction
verfasst von: J. Hui
W. Huishan, PhD
L. Tao
Y. Zhonglu
Z. Renteng
H. Hongguang
Publikationsdatum: 15.12.2016
Verlag: Springer Medizin
Erschienen in: Herz / Ausgabe 8/2017
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI: https://doi.org/10.1007/s00059-016-4517-2

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2017

The safety and efficacy of cardiac contractility modulation in heart failure

Cardiac computed tomography

Kardiogener Schock

ESC-Leitlinie 2017 „Peripheral Arterial Diseases“ – das sind die Neuerungen